Adult Acute Myeloid Leukemia Clinical Trial
Official title:
A Multicenter Clinical Study of Microtransplantation Combined With Azacytidine to Improve the Efficacy of Elderly Acute Myeloid Leukemia
Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.
Microtransplantation, which combines chemotherapy with adoptive infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC). Data from more than 70 elderly AML patients who received microtransplantation in Beijing showed that the remission rate and 2-year disease-free survival (DFS) reach 75-82% and 32-39% respectively, and microchimerisms (donor cells<1%) were detected without GVHD. The results have been clinically validated in several other centers in China, United States and Australia. In this study, azacytidine, decitabine, BCL / 2 inhibitor and other drugs combined with micro transplantation were used in elderly AML in order to improve the curative effect. Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01146223 -
Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
|
N/A | |
| Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
| Completed |
NCT01807091 -
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
|
N/A | |
| Recruiting |
NCT03114670 -
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
|
Phase 1 | |
| Recruiting |
NCT05429632 -
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
|
Phase 3 | |
| Active, not recruiting |
NCT03226418 -
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT06329999 -
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
|
N/A | |
| Completed |
NCT01484015 -
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
|
Phase 1 | |
| Completed |
NCT01041443 -
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
Phase 1 | |
| Not yet recruiting |
NCT03283228 -
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
|
N/A | |
| Completed |
NCT01251575 -
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT06045819 -
Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)
|
||
| Withdrawn |
NCT00101140 -
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
|
Phase 2 |